KMDA — KAMADA LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1567529 ·
Last close
$8.16
Market Cap
$470.92M
52W High
$8.96
52W Low
$6.28
ADV30
100,642
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 52,034,000 | 23,335,000 | 10,371,000 | 7,990,000 | 382,716,000 | 75,317,000 | 114,348,000 |
| Jun 2026 | 54,921,000 | 22,467,000 | 9,510,000 | 9,262,000 | 383,162,000 | 29,473,000 | 113,604,000 |
| Mar 2026 | 45,240,000 | 19,116,000 | 6,953,000 | 4,132,000 | 383,021,000 | 32,922,000 | 123,634,000 |
| Dec 2025 | 44,678,000 | 16,967,000 | 3,551,000 | 3,562,000 | 378,710,000 | 75,469,000 | 109,640,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$35,759,000
Investing CF
$-50,104,000
Financing CF
$-21,785,000
CapEx
$-9,444,000
Dividends Paid
$-14,421,000
Buybacks
—
EPS Diluted TTM
$0.38
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-18,101,000
Inventory
$86,875,000
Receivables
$42,566,000
ST Investments
$40,660,000
EBIT TTM
$27,720,000
Pretax Income TTM
$26,681,000
Interest Exp TTM
$1,039,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$191,848,992
EBITDA
$41,494,000
Free Cash Flow
$15,506,375
Enterprise Value
$400,136,992
Total Cash
$70,133,000
Total Debt
$11,801,000
Shares Out
57,710,305
Trailing EPS
$0.38
Book Value
$4.66
ROE
8.4%
ROA
4.6%
Div Yield
2.14%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 180,460,000 | 26,233,000 | 20,198,000 | 378,710,000 | 109,640,000 | 269,070,000 | 25,490,000 |
| Dec 2024 | 160,953,000 | 20,051,000 | 14,462,000 | 372,255,000 | 112,791,000 | 259,464,000 | 47,594,000 |
| Dec 2023 | 142,519,000 | 10,064,000 | 8,284,000 | 354,907,000 | 110,886,000 | 244,021,000 | 4,315,000 |
| Dec 2022 | 129,339,000 | 4,532,000 | -2,321,000 | 322,379,000 | 146,359,000 | 176,020,000 | 28,586,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.60
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $8.07 · call volume: 0 · put volume: 15
Expected Move to 2027-05-21:
±$3.30
(40.89%) —
implied range
$4.77 –
$11.37
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMRN | AMARIN CORP PLC\UK | $473.82M | $11.27 | — |
| STTK | Shattuck Labs, Inc. | $467.46M | $4.59 | — |
| AQST | Aquestive Therapeutics, Inc. | $465.04M | $3.70 | — |
| NGNE | Neurogene Inc. | $478.19M | $23.10 | — |
| IMMP | IMMUTEP Ltd | $480.43M | $3.26 | — |
News headlines (Yahoo Finance, 1h cache)
Kamada Ltd (KMDA) (Q3 2026) Earnings Call Highlights: Record Nine-Month Revenue and Raised ...
2026-11-09 21:06 · Yahoo
Kamada Ltd. Q3 2026 Earnings Call Summary
2026-11-09 17:52 · Yahoo
Kamada (KMDA) Q3 2026 Earnings Call Transcript
2026-11-09 17:13 · Yahoo
Kamada Q3 Earnings Call Highlights
2026-11-09 15:14 · Yahoo
Kamada (KMDA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
2026-11-09 13:30 · Yahoo
Kamada (KMDA) Surpasses Q3 Earnings Estimates
2026-11-09 12:25 · Yahoo
Kamada: Q3 Earnings Snapshot
2026-11-09 12:17 · Yahoo
Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027
2026-11-09 12:02 · Yahoo
Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
2026-11-09 12:00 · Yahoo
Ahead of Kamada (KMDA) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
2026-11-05 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.